KT-621

Phase 2Small molecule

KKymera Therapeutics, Inc.

KT-621 is one of 43 small molecule programs targeting Atopic Dermatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic DermatitisActive, not recruiting

AsthmaActive, not recruiting

Asthma (diagnosis)Recruiting

Eosinophilic AsthmaRecruiting

Atopic DermatitisPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Asthma (diagnosis)Phase 2

Recruiting

Eosinophilic AsthmaPhase 2

Recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Xolair

Roche

Preclinical

25 3

KT-621

KKymera Therapeutics, Inc.

Phase 2

5 4

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 5

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 6

DUPIXENT

Regeneron

Preclinical

1 7

Aclidinium Bromide

AstraZeneca

Preclinical

—8

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

2 9

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 10

Inhaled Albuterol

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Eosinophilic Asthma

NCT07323654

Q2 2028

Phase 2Active, not recruiting

Atopic Dermatitis

NCT07217015

Q4 2028

Phase 2Recruiting

Asthma (diagnosis)

NCT07677059

Clinical

Trials by Indication[1]

Atopic Dermatitis2 trials

Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

Completed·KKymera Therapeutics, Inc.·Phase 1·NCT06945458·22 enrolled

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study With an Open-label Period Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

Active, not recruiting·KKymera Therapeutics, Inc.·Phase 2·NCT07217015·200 enrolled

Adult1 trial

First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants

Completed·KKymera Therapeutics, Inc.·Phase 1·NCT06673667·118 enrolled

Asthma (Diagnosis)1 trial

A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

Recruiting·KKymera Therapeutics, Inc.·Phase 2·NCT07677059·264 enrolled

Eosinophilic Asthma1 trial

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants With Uncontrolled Moderate to Severe Eosinophilic Asthma

Recruiting·KKymera Therapeutics, Inc.·Phase 2·NCT07323654·264 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for KT-621. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KT-621 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KT-621. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kymera Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKymera Therapeutics, Inc.

KT-621

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Q4 2028

Trials by Indication[1]

Atopic Dermatitis2 trials

Adult1 trial

Asthma (Diagnosis)1 trial

Eosinophilic Asthma1 trial

References

Drug Info

Quick Facts

Related News